Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | CRYAB | P02511 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PTGES | O14684 | 4/20 | 0.79 |
| ▸ | FNTA | P49354 | 1/20 | 0.74 |
| ▸ | FNTB | P49356 | 1/20 | 0.74 |
| ▸ | CRYAA | P02489 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.61 |
| ▸ | HMGCR | P04035 | 1/20 | 0.61 |
| ▸ | PREP | P48147 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanosterol SCHEMBL16994483 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL145834 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL14240642 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL14536063 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL14360758 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL2154745 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL145835 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL1696473 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL19194030 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 | |
| Lanosterol SCHEMBL21348006 | 1.00 | MAPT (1.00) | MAPTUSP2ALDH1A1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023245086-A1 | HUMORAL IMMUNE ACTIVATORS FOR THE TREATMENT OF HUMORAL IMMUNOSUPPRESSED PATHOLOGIES, CANCER AND INFECTIOUS DISEASE AND HUMORAL IMMUNE SUPPRESSORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Navrogen, Inc. (US) | 2023-12-21 | — | — | WO | claimed |
| US-20120136581-A1 | Method of Diagnosing Asphyxia | BIOCRATES LIFE SCIENCES AG (AT) | 2012-05-31 | — | — | US | claimed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | claimed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | claimed |
| EP-2249161-A1 | Method of diagnosing asphyxia | BIOCRATES Life Sciences AG (AT) | 2010-11-10 | — | — | EP | claimed |
| CN-118973585-A | DHCR24 inhibiting compounds | 莱顿教学医院 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023245086-A1 | HUMORAL IMMUNE ACTIVATORS FOR THE TREATMENT OF HUMORAL IMMUNOSUPPRESSED PATHOLOGIES, CANCER AND INFECTIOUS DISEASE AND HUMORAL IMMUNE SUPPRESSORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Navrogen, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230330120-A1 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR REGROWTH | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230330120-A1 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR REGROWTH | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20230242538-A1 | PanK Modulators and Methods Using Same | UNIV YALE (US) | 2023-08-03 | — | — | US | disclosed |
| US-20220133744-A1 | COMPOSITION OF LANOSTEROL PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | disclosed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| EP-0591165-A1 | HETEROCYCLIC STEROID COMPOUNDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5219879-A | Anticholesterol agents | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0276823-B1 | 14,15-SUBSTITUTED LANOSTEROLS AND THEIR USE AS HYPOCHOLESTEROLEMIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991013903-A1 | HETEROCYCLIC STEROID COMPOUNDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-09-19 | — | — | WO | disclosed |
| US-5041432-A | Enzyme inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-20 | — | — | US | disclosed |
| US-5034548-A | Enzyme inhibitors for reducing serum cholesterol | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0276823-A2 | 14,15-Substituted lanosterols and their use as hypocholesterolemic agents | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242538-A1 | PanK Modulators and Methods Using Same | PANK1, PANK2, PANK3 | MAPT 818/4885USP2 2910/4885ALDH1A1 3646/4885 |
| US-20220133744-A1 | COMPOSITION OF LANOSTEROL PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, LSS, CYP46A1 | MAPT 3154/4885USP2 3961/4885ALDH1A1 1273/4885 |
| US-20230330120-A1 | COMPOSITION FOR PREVENTING HAIR LOSS OR PROMOTING HAIR REGROWTH | WNT1, WNT3A, WNT3 | MAPT 1717/4885USP2 1481/4885ALDH1A1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.